What MBrace Therapeutics does

MBrace Therapeutics is a privately held, clinical-stage biopharmaceutical company developing first-in-class antibody-drug conjugates (ADCs) for the treatment of solid tumors. The company is built on the proprietary SPARTA technology platform, an in vivo antibody selection and target discovery system developed at Rutgers Cancer Institute of New Jersey by scientific founders Renata Pasqualini, Ph.D., and Wadih Arap, M.D., Ph.D. The pipeline is anchored by MBRC-101, a humanized anti-EphA5 IgG1 antibody conjugated to monomethyl auristatin E (MMAE) currently in Phase 1/1b trials for advanced refractory solid tumors (NCT06014658), alongside MBRC-201 in Phase 1/2 development for metastatic castration-resistant prostate cancer, breast, colorectal, pancreatic, and NSCLC indications. Earlier-stage programs MBRC-301 and MBRC-401 extend the pipeline, and three international patent families are pending covering antibody production against intracellular targets — a class previously inaccessible to ADC approaches.

The core technology stack combines in vivo antibody selection (SPARTA) for tumor-localizing, specific, and internalizing antibodies with MMAE payload chemistry and a proprietary intracellular-target manufacturing capability. MBrace is headquartered in San Diego, California with an R&D laboratory at the NJ Bioscience Center in North Brunswick, and operates with 11–50 employees. The company has been recognized at the 11th Annual World ADC Awards ("Most Promising Clinical Candidate" for MBRC-101) and presents regularly at ASCO, AACR, and SABCS.

MBrace is pre-revenue and does not currently generate commercial product sales or licensing income. The business model is clinical-stage biotech: capital is raised through equity financings and deployed into R&D, clinical trials at multiple U.S. sites (including NEXT Oncology-Dallas), and platform development, with the long-term intent of obtaining regulatory approval and commercializing ADC therapeutics for cancer patients refractory to standard of care. The company has raised over $110 million to date across a $25M Series A (Venrock, Alta Partners) and an $85M Series B led by TPG in November 2023, with participation from Avidity Partners, Cowen Healthcare Investments, and The Rise Fund. Future go-to-market upon approval is expected to involve specialty pharmacies, hospital buying groups, and oncology specialty distributors, potentially supplemented by partnership deals.

Name

MBrace Therapeutics

Legal name

MBrace Therapeutics, Inc.

Website

https://mbracetrx.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

MBrace Therapeutics is a clinical-stage biopharmaceutical company developing first-in-class antibody-drug conjugates (ADCs) for cancer, using its proprietary SPARTA in vivo antibody selection platform to identify novel tumor targets, with two candidates (MBRC-101, MBRC-201) in Phase 1/2 trials for solid tumors.

Ownership category

akta.pro rank

Product category

Antibody-Drug Conjugates

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Antibody-Drug Conjugates (ADCs) & Antibody Conjugates (HLAAAAAE)

akta.pro secondary industries

CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)

Keywords

• Antibody-drug conjugates
• Oncology biopharmaceuticals
• Clinical-stage drug development
• Targeted cancer therapy
• ADC platform

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. ADC Drug Development and Commercialization: MBrace is a clinical-stage biopharmaceutical company focused on developing novel antibody-drug conjugates for cancer treatment. As a pre-revenue company, it does not currently generate commercial revenue. The company is advancing multiple ADC candidates through clinical development with the goal of obtaining regulatory approval and commercializing treatments for cancer patients.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

MBrace Therapeutics is a clinical-stage biopharmaceutical company developing first-in-class antibody-drug conjugates (ADCs) for the treatment of cancer. Its lead assets, MBRC-101 and MBRC-201, are in Phase 1/2 development targeting solid tumors, supported by a proprietary SPARTA platform that enables targeting of tumor-specific intracellular antigens. The company is pre-revenue and intends to monetize assets via one-time out-licensing deals with strategic pharmaceutical partners.

Product overview

MBrace Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of first-in-class antibody-drug conjugates (ADCs) targeting novel cancer antigens. The company's core products include MBRC-101 and MBRC-201, both currently in Phase 1/2 clinical trials for solid tumors, with additional pipeline candidates MBRC-301 and MBRC-401 in earlier stages of development. These ADC candidates are developed using the proprietary SPARTA technology platform for antibody selection and target discovery, which enables identification of novel tumor targets and selection of antibodies with optimal properties for ADC development.

Differentiator

Problem solved

Functional benefit

Products and services

• MBRC-101

Quantifiable outcome

• EphA5 expression detected in greater than 80% of triple-negative breast cancer and HR+ breast cancer tissue samples
• +3 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Rutgers Cancer Institute of New JerseycoreStrategic or Co-development Partner · 1 June 2020MBrace has a sponsored research agreement with Rutgers Cancer Institute of New Jersey. The company was founded based on technology developed at Rutgers, and co-founders Renata Pasqualini and Wadih Arap are professors at Rutgers. The SPARTA technology was developed at Rutgers, The State University of New Jersey.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Pyxis Oncology: Clinical-stage ADC and immuno-oncology company developing novel antibody-drug conjugates for solid tumors with a similar Series B/C stage profile and focus on first-in-class targets — comparable in size, therapeutic area, and platform-driven strategy.
• Bolt Biotherapeutics: Clinical-stage immuno-oncology company developing antibody-drug conjugates with immune-stimulating payloads for solid tumors, sharing MBrace's clinical-stage profile and focus on novel ADC mechanisms in oncology.
• ProfoundBio: Clinical-stage biopharmaceutical company developing novel antibody-drug conjugates with proprietary linker and payload technologies for cancer — comparable in clinical stage, therapeutic focus, and ADC platform-driven approach to MBrace.
• Mersana Therapeutics: Clinical-stage biopharmaceutical company developing a pipeline of antibody-drug conjugates (ADCs) for oncology, with similar size, stage, and strategic focus on novel linker/payload platforms and solid tumor targets — directly comparable to MBrace's business model and clinical approach.

Broad incumbents

• ImmunoGen (AbbVie): Pioneer in ADC development with approved products including Elahere, acquired by AbbVie for $10.1 billion in 2024 — comparable as an established ADC player in oncology with overlapping clinical and commercial focus on solid tumor ADCs.
• Seagen (Pfizer): Industry-leading ADC company with multiple approved oncology products (Adcetris, Padcev, Tukysa, Tivdak) acquired by Pfizer for $43 billion — directly comparable as the ADC market leader; notably MBrace's CSO Steve Alley built his career at Seagen.
• Daiichi Sankyo: Major global pharmaceutical company that co-developed Enhertu and Datroway with AstraZeneca, establishing itself as a top-tier ADC innovator — comparable as a leading ADC developer and frequent licensor of ADC assets.
• Genentech / Roche: Major pharmaceutical company with multiple approved ADCs including Kadcyla and Polivy, and an active ADC pipeline — comparable as a large established ADC player in oncology that competes in the same indication space as MBrace's candidates.
• AstraZeneca: Global pharmaceutical company with a leading ADC franchise through its Daiichi Sankyo partnership (Enhertu, Datroway) and aggressive inorganic ADC strategy — comparable as a major oncology player actively acquiring and partnering with ADC developers.

Emerging players

• Tubulis: European clinical-stage biotech developing next-generation antibody-drug conjugates with proprietary conjugation technologies and novel payloads — comparable as an ADC platform play but primarily focused on different technology dimensions than MBrace's SPARTA in vivo selection.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat2 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/mbrace-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds2 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MBrace Therapeutics